However, with the rise of the incretin-based pharmacotherapies, including dual and triple incretin agonists and their associated remarkable weight-loss effects (almost now equivalent to some forms of bariatric surgery) [14,15], it seems likely that future treatment algorithms for obesity will place less emphasis on the relative positioning of each management option generally, but rather focus on the needs of individuals. This evidence concerns the gene GCG and obesity disorder.